公开(公告)号：US20240350529A1

公开(公告)日：2024-10-24

申请号：US18588605

申请日：2024-02-27

申请人： SYNEDGEN, INC.

发明人： Shenda M. Baker ,  William P. Wiesmann ,  Stacy Marie Townsend

IPC分类号： A61K31/726 ,  A61K9/00 ,  A61K9/08 ,  A61K9/14 ,  A61K9/48 ,  A61K45/06 ,  A61K47/10

CPC分类号： A61K31/726 ,  A61K9/0078 ,  A61K9/08 ,  A61K9/14 ,  A61K9/48 ,  A61K45/06 ,  A61K47/10

摘要： Described herein are methods for treating or preventing a disease or disorder of the pulmonary system (e.g., cystic fibrosis), respiratory or digestive system in a subject, the methods comprising administering compounds or compositions comprising water soluble polyglucosamine and derivatized polyglucosamine.

公开(公告)号：US20240342239A1

公开(公告)日：2024-10-17

申请号：US18294688

申请日：2022-08-04

申请人： Zambon S.P.A.

发明人： Paola Castellani

IPC分类号： A61K38/12 ,  A61K9/00 ,  A61P35/00

CPC分类号： A61K38/12 ,  A61K9/0078 ,  A61P35/00

摘要： The present invention relates to the use of Colistin for reducing the frequency of pulmonary exacerbations in patients suffering from Non-Cystic Fibrosis Bronchiectasis (NCFB), wherein said patients are infected with P. aeruginosa.

公开(公告)号：US20240307302A1

公开(公告)日：2024-09-19

申请号：US18681202

申请日：2022-08-03

申请人： LEIUTIS PHARMACEUTICALS LLP

发明人： Chandrashekhar Kocherlakota ,  James Thomas Brenna ,  Sesha Durga Kumar Kothapalli ,  Nagaraju Banda ,  Arjun Narala ,  Srinath Akula

IPC分类号： A61K9/00 ,  A61K31/00 ,  A61K31/202 ,  A61K31/4045 ,  A61K31/58 ,  A61K47/24

CPC分类号： A61K9/0078 ,  A61K31/202 ,  A61K31/4045 ,  A61K31/58 ,  A61K31/658 ,  A61K47/24

摘要： Inflammatory disorders of the lung are induced by COVID-19 disease, asthma, and numerous other disorders. Omega-3 fatty acids (O3FA), particularly docosahexaenoic acid (DHA), docosapentaenoic acid (DPA) or cicosapentaenoic acid (EPA), have known anti-inflammatory and pro-resolving properties. Reduction of lung pathology and inflammation will be accomplished by a mixture incorporating O3FA that is suitable for nebulization using formulas and nebulization apparatus known in the art. The O3FA may be delivered in the form of ethyl esters (EE) or free fatty acid (FEA) oils or non-phosphate-containing glycerolipids or as phospholipids (PL) or as any other form known in the art. The mixture can also be delivered in any of the other forms of inhaled droplet or solids for inhalation known in the art. The patient will inhale for a therapeutically effective period of time to reduce inflammation and improve breathing.

公开(公告)号：US12059447B2

公开(公告)日：2024-08-13

申请号：US16988627

申请日：2020-08-08

申请人： Locus Solutions IPCo, LLC

发明人： Sean Farmer ,  Ken Alibek

IPC分类号： A61K9/00 ,  A61K36/53 ,  A61K47/10 ,  A61K47/18

CPC分类号： A61K36/53 ,  A61K9/0043 ,  A61K9/0075 ,  A61K9/0078 ,  A61K47/10 ,  A61K47/183

摘要： The present invention provides materials and methods for treating symptoms of neurological conditions. More specifically, the subject invention provides compositions and methods of their use for treating one or more symptoms and/or comorbidities of a neurological condition such as an infection, a neurodevelopmental disease, and/or a neurodegenerative disease. In preferred embodiments, the composition is administered to the subject via nasal administration.

公开(公告)号：US12048692B2

公开(公告)日：2024-07-30

申请号：US18137919

申请日：2023-04-21

申请人： THERAVANCE BIOPHARMA R&D IP, LLC

发明人： Christopher Noel Barnes ,  Glenn D. Crater ,  Edmund J. Moran ,  Srikanth Pendyala

IPC分类号： A61K31/444 ,  A61K9/00 ,  A61K31/135 ,  A61P11/06 ,  A61K45/06

CPC分类号： A61K31/444 ,  A61K9/0078 ,  A61K31/135 ,  A61P11/06 ,  A61K45/06

摘要： Methods for treating chronic obstructive pulmonary disease (COPD) in a patient are disclosed. In the methods, a patient having COPD is selected for treatment based on the patient's peak inspiratory flow rate (PIFR) and percent predicted force expiratory volume in one second (FEV1); and a bronchodilator is administered to the selected patient using a nebulizer. Administration of a bronchodilator to patients having low PIFR and a percent predicted FEV1 less than 50 percent using a nebulizer as the inhalation delivery device provides significantly greater improvements in trough FEV1 and trough forced vital capacity (FVC) compared to administration of a bronchodilator to such patients using a dry powder inhaler.

公开(公告)号：US20240245768A1

公开(公告)日：2024-07-25

申请号：US18562606

申请日：2022-05-20

申请人： LACTIGA, INC.

发明人： Viraj Mane ,  Rikin Mehta

IPC分类号： A61K39/395 ,  A61K9/00 ,  A61K35/20 ,  A61P31/14

CPC分类号： A61K39/39508 ,  A61K9/0078 ,  A61K35/20 ,  A61P31/14

摘要： A composition and method of preparing the composition is provided. The composition is for inhalation to treat respiratory syncytial virus. The composition includes a poly clonal antibody derived from human breastmilk. In particular, the composition includes intact antibodies representing more than about 81% of total antibodies. The total antibodies include intact antibodies and degraded antibodies.

公开(公告)号：US12042514B2

公开(公告)日：2024-07-23

申请号：US18122478

申请日：2023-03-16

申请人： Tygrus, LLC

发明人： Paul Bundschuh ,  Lawrence Carlson ,  Shawn Dolan ,  Andrew M. Yaksic

IPC分类号： A61K33/42 ,  A61K9/00 ,  A61K31/137 ,  A61K31/198 ,  A61K31/215 ,  A61K31/4045 ,  A61K31/405 ,  A61K31/4704 ,  A61K31/513 ,  A61K31/569 ,  A61K31/573 ,  A61K31/58 ,  A61K31/616 ,  A61K31/675 ,  A61K31/7056 ,  A61K31/7076 ,  A61K33/00 ,  A61K33/04 ,  A61K33/20 ,  A61K33/40 ,  A61K45/06 ,  A61P31/04 ,  A61P31/10 ,  A61P31/14 ,  A61P31/16

CPC分类号： A61K33/42 ,  A61K9/0078 ,  A61K31/137 ,  A61K31/198 ,  A61K31/215 ,  A61K31/4045 ,  A61K31/405 ,  A61K31/4704 ,  A61K31/513 ,  A61K31/569 ,  A61K31/573 ,  A61K31/58 ,  A61K31/616 ,  A61K31/675 ,  A61K31/7056 ,  A61K31/7076 ,  A61K33/00 ,  A61K33/04 ,  A61K33/20 ,  A61K33/40 ,  A61K45/06 ,  A61P31/04 ,  A61P31/10 ,  A61P31/14 ,  A61P31/16

摘要： Method and composition for treating or preventing a respiratory illness. The method includes administering at least one dose of a pharmaceutically acceptable fluid having a pH less than 3.0 into contact with at least one region of the respiratory tract present in a patient in need thereof. Respiratory illness that can be treated include COVID-19.

公开(公告)号：US12036355B2

公开(公告)日：2024-07-16

申请号：US17051382

申请日：2019-05-03

申请人： Boehringer Ingelheim International GmbH

发明人： Stephen Terence Dunne ,  Dana Huesch ,  Peter Rolf Werner Langguth

IPC分类号： A61M11/00 ,  A61F9/00 ,  A61K9/00 ,  A61K9/107 ,  A61K9/127 ,  A61K31/58 ,  A61K47/24 ,  A61K47/28 ,  A61M15/00 ,  B05B9/08 ,  B05B11/00 ,  B05B11/02 ,  B05B11/10 ,  B05B17/00

CPC分类号： A61M11/007 ,  A61F9/0008 ,  A61K9/0078 ,  A61K9/127 ,  A61K47/24 ,  A61K47/28 ,  B05B9/0822 ,  B05B17/00 ,  A61K9/0048 ,  A61K9/1075 ,  A61K31/58 ,  A61M15/0035 ,  A61M2205/071 ,  B05B11/0054 ,  B05B11/026 ,  B05B11/028 ,  B05B11/1091

摘要： A system includes a nebulizer for nebulizing a fluid from a container and such a container containing a fluid and are proposed. The fluid is a non-newtonian fluid, in form of a suspension or emulsion or a liposomal fluid or a gel. The nebulizer includes a fluid pump for withdrawing the fluid in doses from the container and pressurizing the respective doses for nebulization through nozzle channels having a hydraulic diameter in the range of 3 to 20 microns at an operational pressure of 5 to 250 MPa.

公开(公告)号：US20240226215A9

公开(公告)日：2024-07-11

申请号：US17972941

申请日：2022-10-25

申请人： Mitchell Lynn Tate

发明人： Mitchell Lynn Tate

IPC分类号： A61K36/19 ,  A61K9/00 ,  A61K36/752 ,  A61K38/44 ,  A61P31/14 ,  A61P31/16

CPC分类号： A61K36/19 ,  A61K9/0053 ,  A61K9/0078 ,  A61K36/752 ,  A61K38/446 ,  A61P31/14 ,  A61P31/16 ,  C12Y115/01001

摘要： An oral product comprising nano-sized, heat tolerable, shelf stable peptides and enzymes. Once the peptides and enzymes are inside the body of a user, they dimerize the nucleic acids of viruses, bacteria and fungi. Thus, the peptides and enzymes are capable of inactivating the genome of pathogens, including without limitation, SARS-CoV-2 and Influenza A/CA/04/2009 (H1N1) virus.

公开(公告)号：US20240226118A1

公开(公告)日：2024-07-11

申请号：US18538065

申请日：2023-12-13

申请人： The U.S.A., as represented by the Secretary, Department of Health and Human Services

发明人： Peter L. Collins ,  Matthias Lingemann ,  Shirin Munir

IPC分类号： A61K31/58 ,  A61K9/00 ,  A61P31/14

CPC分类号： A61K31/58 ,  A61K9/0043 ,  A61K9/0078 ,  A61P31/14

摘要： Embodiments of a method for inhibiting viral infection in a subject are provided herein. In some embodiments, the method comprises administration of a competitive antagonist of ouabain binding to ATP1A1 to inhibit respiratory syncytial virus infection in the subject.